Use of nonprescription medications by patients with congestive heart failure

M L Ackman1, J B Campbell, K A Buzak

  • 1Regional Pharmacy Service, Capital Health, Edmonton, Alberta, Canada.

Insights

Patients with congestive heart failure (CHF) use nonprescription therapies similarly to those without heart conditions. CHF patients show caution with potentially harmful cough and cold products.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Nonprescription therapies are widely used, but their utilization patterns in patients with congestive heart failure (CHF) are not well-defined.
  • Understanding the use of over-the-counter medications in CHF patients is crucial for managing potential drug interactions and adverse effects.

Purpose of the Study:

  • To determine the usage patterns of nonprescription therapies among patients diagnosed with congestive heart failure (CHF).
  • To compare the nonprescription therapy utilization of CHF patients with an age- and gender-matched control group without heart conditions.

Main Methods:

  • A survey questionnaire was administered to patients attending an ambulatory CHF clinic and to a control group.
  • Participants completed the survey at home, detailing nonprescription therapies used at least once weekly.
  • The study included 180 CHF patients and 133 control subjects, matched for age and gender.

Main Results:

  • The most common nonprescription categories for both groups were vitamins/minerals, pain relievers, herbal products, antacids, and laxatives, with no significant differences.
  • CHF patients used significantly fewer cough and cold products (9% vs. 17%) and oral decongestants (0.6% vs. 5%) compared to controls.
  • Conversely, CHF patients reported higher use of nutritional supplements (17% vs. 4%) than the control group.

Conclusions:

  • Overall nonprescription therapy use in CHF patients is comparable to the general population without heart conditions.
  • CHF patients exhibit appropriate caution by avoiding potentially harmful cough and cold products.
  • Observed differences in specific nonprescription product use highlight potential patient awareness regarding medication safety in heart failure.
Abstract

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...